Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data

Kit N. Simpson,Birgitta Dietz,Robert W. Baran,Kevin W. Garren,Sharon A. Riddler,Menaka Bhor,Richard Haubrich

Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data

2011

Kit N. Simpson
Birgitta Dietz
Robert W. Baran
Kevin W. Garren
Sharon A. Riddler
Menaka Bhor
Richard Haubrich

Background This study examines the cost and consequences of initiating an ARV regimen including Lopinavir/ritonavir (LPV/r) or Efavirenz (EFV), using data from a recent clinical trial in a previously published model of HIV-disease.

Keywords:

Nursing
Clinical trial
Alternative medicine
Lipoatrophy
Lopinavir/ritonavir
Ritonavir
Regimen
Disease
Efavirenz
Lopinavir
Medicine
Environmental health
HIV/AIDS
Gerontology
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations